Highlights Otsuka Corporation

Equities

4768

JP3188200004

IT Services & Consulting

Delayed Japan Exchange Other stock markets 02:30:00 13/01/2026 GMT			5-day change	1st Jan Change
3,226.00 ^JPY	+0.94%		+0.84%	-0.19%

01-12	Ionis Pharmaceuticals, Inc. Provides Additional Updates on Key Milestones Expected in 2026	CI
11-25	US FDA approves Otsuka's drug for a type of kidney disease	RE

Highlights

01-12	Ionis Pharmaceuticals, Inc. Provides Additional Updates on Key Milestones Expected in 2026	CI
12-28	Final dividend	FA
11-25	US FDA approves Otsuka's drug for a type of kidney disease	RE
31/10/25	Otsuka Corporation Provides Year End Dividend Guidance for the Fiscal Year Ending December 31, 2025	CI
31/10/25	Otsuka Corp Nine-Month Profit Up 27%	MT
10/10/25	Otsuka Corporation has positive outlook and boosts guidance
20/09/25	Otsuka and Lundbeck Receives Complete Response Letter from U.S. FDA for sNDA of REXULTI®? (Brexpiprazole) in Combination with Sertraline for the Treatment of Adults with PTSD	CI
01/08/25	Otsuka Profit Increases 27% in H1	MT
01/08/25	Otsuka Corporation Revises Consolidated Earnings Guidance for the Full Year Ending December 31, 2025	CI
01/08/25	Otsuka Corporation Announces Dividend for the Second Quarter Ended June 30, 2025, Payable on September 3, 2025	CI
21/07/25	Lundbeck, Otsuka's PTSD Treatment Combination Fails to Win US FDA Committee Recommendation	MT
18/07/25	US FDA advisers recommend against Otsuka's PTSD combination treatment	RE
26/06/25	Ex-dividend day for interim dividend	FA
06/06/25	Otsuka's kidney disease therapy trial results heat up battle with rival Vera	RE
01/05/25	Otsuka's Fiscal Q1 Profit Jumps 24% as Sales Rise 18%	MT
30/04/25	Otsuka Corporation Provides Consolidated Earnings Guidance for the Six Months Ending June 30, 2025 and Full Year Ending December 31, 2025	CI
30/04/25	Otsuka Corporation Provides Dividend Guidance for the First Half of 2025 and Full Year Ending December 31, 2025	CI
02/02/25	Otsuka Corporation Reports Earnings Results for the Full Year Ended December 31, 2024	CI
26/12/24	Final dividend	FA
26/11/24	Otsuka Completes Share Repurchase Program	MT
13/11/24	Otsuka, ICU Medical Launch Joint Venture in North America	MT
13/11/24	Jefferies Adjusts Otsuka's Price Target to 4,400 Yen From 4,090 Yen, Keeps at Buy	MT
08/10/24	Irlab receives milestone payment of USD 2.5 million linked to Phase 1 study with IRL757	FW
03/10/24	IRLAB Therapeutics AB Announces Positive Data from the First Part of Phase I Study with the Drug Candidate IRL 757	CI
29/07/24	Nikkei Rises Ends Eight-Session Losing Streak on Monetary Tightening Bets	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies Trading Ideas

Highlights Otsuka Corporation

Equities

4768

JP3188200004

IT Services & Consulting

Highlights

Filters